PremiumRatingsAC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating AC Immune’s Strategic Advances and Financial Highlights AC Immune announces additional data from Phase 2 study of VacSYn clinical trial PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Biotech Alert: Searches spiking for these stocks today AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership PremiumCompany AnnouncementsAC Immune’s Promising Trial Results for Parkinson’s Therapy AC Immune SA Reports Profitable Q3 2024 Results AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year